title: The effect of combination therapy of hyperbaric oxygen, meropenem, and selective nitric oxide synthase inhibitor in experimental acute pancreatitis.
abstract: Despite the new diagnostic and therapeutic advancements, acute pancreatitis has still high rate of morbidity and mortality. We aimed to evaluate the effects of hyperbaric oxygen (HBO) therapy alone or combined with S-methylisothiourea (SMT), and meropenem (MER) therapy in an experimental rat model of acute necrotizing pancreatitis. Rats were randomly divided into 8 groups, and acute pancreatitis was induced in all groups except group 1. Treatment protocols were saline for group 2, SMT for group 3, SMT + MER for group 4, SMT + HBO for group 5, HBO for group 6, HBO + MER for group 7, and MER for group 8. All surviving animals were killed 48 hours after the induction of pancreatitis, and specimens were collected. Oxidative stress parameters, histopathologic scores and amylase levels were better in treatment groups than in the positive control group (group 2). The most favorable results were obtained in HBO treatment groups, especially in HBO + MER group (group 7). Our results indicate that adding HBO therapy to the antibiotic therapy will decrease oxidative stress parameters, serum amylase levels, and histopathological score. We suggest that adding the HBO therapy as an adjunctive to the treatment protocol of acute necrotizing pancreatitis may yield improvement in the morbidity and mortality of the disease.
authors.affiliation: Department of Internal Medicine, Gülhane School of Medicine, Ankara, Turkey.
authors.forename: A Turan
authors.initials: AT
authors.lastname: Isik
authors.forename: M Refik
authors.initials: MR
authors.lastname: Mas
authors.forename: Bilgin
authors.initials: B
authors.lastname: Comert
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yasar
authors.forename: Ahmet
authors.initials: A
authors.lastname: Korkmaz
authors.forename: Cemal
authors.initials: C
authors.lastname: Akay
authors.forename: Salih
authors.initials: S
authors.lastname: Deveci
authors.forename: Ilker
authors.initials: I
authors.lastname: Tasci
authors.forename: Nuket
authors.initials: N
authors.lastname: Mas
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Ates
authors.forename: I Hakki
authors.initials: IH
authors.lastname: Kocar
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000378:metabolism; D006931:Hyperbaric Oxygenation; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D000077731:Meropenem; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019283:Pancreatitis, Acute Necrotizing / Q000139:chemically induced / Q000201:enzymology / Q000628:therapy*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D013656:Taurocholic Acid; D013845:Thienamycins / Q000627:therapeutic use*
chemical_list: D004791:Enzyme Inhibitors; D013845:Thienamycins; D008315:Malondialdehyde; D013656:Taurocholic Acid; D005979:Glutathione Peroxidase; D019001:Nitric Oxide Synthase; D013482:Superoxide Dismutase; D000077731:Meropenem